Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas (Nasdaq: ARVN) will present Phase 1 human data for ARV-102, an oral PROTAC degrader targeting LRRK2, at AD/PD 2026 in Copenhagen. The presentation on March 18, 2026 at 3:30 PM CET covers safety, pharmacokinetics, and pharmacodynamics in participants with Parkinson’s disease.
Arvinas (Nasdaq: ARVN) reported 4Q and full‑year 2025 results and a corporate update on Feb 24, 2026. Key items: cash, cash equivalents and marketable securities of $685.4M at year‑end; cash runway into the second half of 2028; multiple clinical readouts and program milestones planned in 2026; Randy Teel named President and CEO.
Pipeline progress includes ARV‑102 AD/PD data in March 2026, ARV‑806 and ARV‑393 clinical updates in 2026, initiation of ARV‑027 healthy‑volunteer trial, and ARV‑6723 Phase 1 planned mid‑2026.
Arvinas (Nasdaq: ARVN) said management will participate in four investor conferences in early March 2026, including TD Cowen, Leerink Global Healthcare, Barclays Global Healthcare, and Jefferies Biotech on the Beach.
Each appearance is a fireside chat with specific times on March 3, 9, 10 and 11; replays will be posted in the Events and Presentations section of the company website.
Arvinas (Nasdaq: ARVN) will report fourth quarter and full year 2025 financial results on February 24, 2026. Management will review results and provide a corporate update via a live webcast at 8:00 a.m. ET.
The webcast is available under “Events and Presentations” on Arvinas’ investor website, and a replay will be posted on www.arvinas.com after the event.
Arvinas (Nasdaq: ARVN) announced that Randy Teel, Ph.D., has been appointed President, Chief Executive Officer, and director effective February 12, 2026. Teel succeeds John Houston, Ph.D., who is retiring as CEO and chair but will remain a board member and provide consulting services. Briggs Morrison, M.D., becomes board chair.
The release highlights Teel’s 20 years of industry experience, his role in Arvinas’ 2018 IPO, the company’s first positive pivotal PROTAC trial, demonstrated CNS pharmacodynamic activity, and over $2 billion raised through financings and partnerships.
PROTAC market (coverage: 7MM) is forecast to grow sharply through 2034 as targeted protein degradation advances across oncology and other indications. Key pipeline assets include vepdegestrant, luxdegalutamide, ASP3082, and DT2216. The report cites ~90 protein-degradation leads, ~20% in clinical development, and PROTACs representing >30% of the protein degradation pipeline. Strategic partnerships include Arvinas collaborations with Pfizer and Novartis, and a Novartis up-front payment of USD 150 million for ARV-766 rights. Notable trial data: Phase III VERITAC-2 met its ESR1m primary endpoint but not the ITT population.
Arvinas (NASDAQ: ARVN) presented preclinical data showing enhanced antitumor activity when its PROTAC BCL6 degrader ARV-393 is combined with glofitamab (CD20×CD3) at ASH 2025.
Key findings: concomitant ARV-393 (3 mg/kg) + glofitamab (0.15 mg/kg) produced 81% tumor growth inhibition (TGI) and sequential dosing produced 91% TGI vs 38% and 36% for each agent alone; higher-dose ARV-393 (6 mg/kg) combinations yielded markedly higher tumor regressions (10/10 and 7/8 mice vs 5/11 and 0/11 for single agents). RNA sequencing showed CD20 upregulation and increased interferon/antigen-presentation gene expression. Arvinas plans to initiate a Phase 1 combination cohort in DLBCL in 2026.
Arvinas (Nasdaq: ARVN) announced that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. and Chief Financial Officer Andrew Saik will present in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The presentation is scheduled for Thursday, December 4, 2025 at 11:00 a.m. ET in New York. A live audio webcast will be available on the company’s Events and Presentations web page.
Arvinas (Nasdaq: ARVN) announced multiple abstracts on vepdegestrant (ARV-471) accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), Dec 9–12, 2025 in San Antonio, TX.
Presentations include subgroup analyses from the phase 3 VERITAC-2 trial versus fulvestrant, ctDNA biomarker analyses from a phase 1/2 study, real-world ESR1 mutation prevalence after 1L therapy, an I-SPY2 endocrine optimization pilot, and a phase 1/2 trial of PF-07248144 combined with vepdegestrant. Pfizer is a development collaborator and Quantum Leap sponsors I-SPY2 EOP. Full abstracts available via the SABCS online program.
Arvinas (NASDAQ: ARVN) reported 3Q2025 results and a corporate update highlighting clinical and preclinical progress, collaboration milestones, and financial positions. Key clinical highlights include ARV-102 showing >90% PBMC LRRK2 reduction and >50% CSF reduction with brain penetration, and ARV-102 effects on distal CSF biomarkers; ARV-806 preclinical potency ~25x–40x versus competitors with >90% degradation for 7 days in models; ARV-027 demonstrated 40–60% muscle polyQ-AR reduction and functional benefit in SBMA mice. Regulatory/commercial: FDA accepted the NDA for vepdegestrant with a PDUFA date of June 5, 2026 and Arvinas/Pfizer will jointly select a commercialization partner. Cash was $787.6M at Sept 30, 2025, funding operations into H2 2028 per management.